Text Size

The Efficacies of The New Paclitaxel-Eluting CoroflexTM Please Stent in Percutaneous Coronary Intervention

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
B. Braun Melsungen AG
Information provided by:
Seoul National University Hospital
ClinicalTrials.gov Identifier:
NCT00699543
First received: June 16, 2008
Last updated: February 1, 2010
Last verified: February 2010
History of Changes
  Purpose

Objectives

: To evaluate the clinical efficacy, angiographic outcomes, and safety of the new paclitaxel-eluting coronary stent (CoroflexTM Please, B Braun, Germany), compared with another paclitaxel-eluting coronary stent system (TaxusTM, Boston Scientific, USA) in the treatment of coronary stenosis.

Study Design

: Prospective, open label, 2: 1 randomized multi-center trial. Patients will be randomized according to the type of drug eluting stent ( CoroflexTM Please vs. TaxusTM). Randomization will also be stratified per hospital for the presence of DM and the presence of long lesions (lesion length > 28mm)

Patient Enrollment

:915 patients enrolled at 13 centers in Korea.

Patient Follow-Up

:Clinical follow-up will occur at 1, 4, 9, 12 months and 2, 3years after intervention. Investigator or designee may conduct follow-up as telephone contacts or office visits.

Primary Endpoint

:Clinically driven Target vessel Revascularization (TVR) at 9 months.

Secondary Endpoints

:A. Clinical safety and efficacy end points

  1. Major Cardiac Adverse Events (MACE; All Death, cardiac death, Myocardial infarction (Q-wave and non-Q wave), TVR)
  2. Target Vessel Failure (TVF; cardiovascular death, myocardial infarction, clinically driven TVR)
  3. Stent thrombosis

B. Angiographic efficacy end points

  1. in-stent binary restenosis by QCA
  2. in-stent and in-lesion late loss by QCA
  3. in-stent and in-lesion MLD and percentage diameter stenosis by QCA immediately after the index procedure and at 9 months of follow-up

Condition Intervention Phase
Coronary Artery Disease
 Device: Coroflex Please stent implantation
Device: Taxus stent implantation
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The Efficacies of The New Paclitaxel-Eluting CoroflexTM Please Stent in Percutaneous Coronary Intervention: Comparison or Efficacy Between COroflex PLEASe ANd TaxusTM Stent

Resource links provided by NLM:

Drug Information available for: Paclitaxel
U.S. FDA Resources

Further study details as provided by Seoul National University Hospital:

Primary Outcome Measures:
  • Clinically driven Target vessel Revascularization (TVR) [ Time Frame: 9 months. ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Major Cardiac Adverse Events (MACE; All Death, cardiac death, Myocardial infarction (Q-wave and non-Q wave), TVR) [ Time Frame: 1, 4, 9, 12 months and 2, 3years ] [ Designated as safety issue: Yes ]
  • Target Vessel Failure (TVF; cardiovascular death, myocardial infarction, clinically driven TVR) [ Time Frame: 1, 4, 9, 12 months and 2, 3years ] [ Designated as safety issue: Yes ]
  • Stent thrombosis [ Time Frame: 1, 4, 9, 12 months and 2, 3years ] [ Designated as safety issue: Yes ]
  • In-stent binary restenosis by QCA [ Time Frame: 9 months ] [ Designated as safety issue: No ]
  • In-stent and in-lesion late loss by QCA [ Time Frame: 9 months ] [ Designated as safety issue: No ]
  • In-stent and in-lesion MLD and percentage diameter stenosis by QCA [ Time Frame: Immediately after the index procedure and at 9 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 915
Study Start Date: July 2008
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: C
Coroflex Please stent implantation
 Device: Coroflex Please stent implantation
Use Coroflex Please stent in the treatment of coronary stenosis
Other Name: Coroflex Please stent
Active Comparator: T
Taxus stent implantation
 Device: Taxus stent implantation
Use Taxus stent in the treatment of coronary stenosis
Other Name: Taxus stent

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • General Inclusion Criteria

    1. Subject must be at least 18 years of age.
    2. Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving the CoroflexTM Please stent and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure.
    3. Subject must have coronary artery stenosis (>50% by visual estimate) with evidence of myocardial ischemia (e.g., stable, unstable angina, myocardial infarction, silent ischemia, positive functional study or a reversible changes in the electrocardiogram (ECG) consistent with ischemia.) or Subject must have significant coronary artery stenosis (>70% by visual estimate)

  • Angiographic Inclusion Criteria

    1. Target lesion(s) must be located in a native coronary artery with visually estimated diameter of ≥ 2.5 mm and ≤ 4.0 mm.
    2. Target lesion(s) must be amenable for percutaneous coronary intervention

Exclusion Criteria

  • General Exclusion Criteria

    1. The patient has a known hypersensitivity or contraindication to any of the following medications:

      • Heparin
      • Aspirin
      • Both Clopidogrel and Ticlopidine
      • Paclitaxel
      • Stainless steel
      • Contrast media(*) (*)Patients with documented sensitivity to contrast media which can be effectively pre-medicated with steroids and diphenhydramine [e.g. rash] may be enrolled. Those with true anaphylaxis to prior contrast media, however, should not be enrolled.
    2. Systemic (intravenous) Paclitaxel use within 12 months.
    3. Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study.
    4. History of bleeding diathesis or known coagulopathy (including heparin- induced thrombocytopenia), or will refuse blood transfusions.
    5. Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months.
    6. An elective surgical procedure is planned that would necessitate interruption of thienopyridines during the first 6 months post enrollment.
    7. Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment).
    8. Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.
    9. Patients with LVEF<25% or those with cardiogenic shock
    10. Patients with acute ST elevation myocardial infarction who requires primary PCI
    11. Patients with acute ST elevation myocardial infarction within 48hrs
    12. Creatinine level ≥ 3.0mg/dL or dependence on dialysis.

  • Angiographic Exclusion Criteria

    1. Patients with significant left main stem stenosis which requires revascularization therapy
    2. Patients who's target lesion has in-stent restenosis at the stented segment of drug-eluting stents or bare metal stents
    3. Target lesions with bifurcating disease which require side branch stenting
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00699543

Sponsors and Collaborators
Seoul National University Hospital
B. Braun Melsungen AG
Investigators
Study Chair: Hyo-Soo Kim, MD, PhD Seoul National University Hospital
Study Chair: In-Ho Chae, MD, PhD Seoul National University Bundang Hospital
Study Chair: Seung-Ho Hur, MD, Ph Keimyung University Dongsan Medical Center
Principal Investigator: Tae-Jin Youn, MD, PhD Seoul National University Bundang Hospital
Principal Investigator: Soo-Joong Kim, MD, PhD Kyunghee University Medical Center
Principal Investigator: Keum-Soo Park, MD, PhD Inha University Hospital
Principal Investigator: Byung-Ok Kim, MD, PhD Inje University Sang-gye Paik Hospital
Principal Investigator: Min-Su Hyon, MD, PhD Soon Chun Hyang University Hospital
Principal Investigator: Sang-Wook Kim, MD, PhD Chung-Ang University Hospital
Principal Investigator: Jong-Seon Park, MD, PhD Yeungnam University
Principal Investigator: Doo-Il Kim, MD, PhD Inje University
Principal Investigator: Tae-Joon Cha, MD, PhD Kosin University Gospel Hospital
Principal Investigator: Sang-Gon Lee, MD, PhD Ulsan University Hospital
Principal Investigator: Hee-Kyoung Jeon, MD, PhD Uijeongbu St. Mary's Hospital
  More Information

No publications provided by Seoul National University Hospital

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Hyo-Soo, Kim, Seoul National University Hospital
ClinicalTrials.gov Identifier: NCT00699543     History of Changes
Other Study ID Numbers: ECO-PLEASANT
Study First Received: June 16, 2008
Last Updated: February 1, 2010
Health Authority: South Korea: Institutional Review Board

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Paclitaxel
 Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 21, 2013